Core Viewpoint - The ongoing investigation into "Contemporary System" has led to significant regulatory actions against companies like Renfu Pharmaceutical and its former controlling shareholder, Contemporary Group, highlighting a strict regulatory stance against abuse of control and violations affecting minority investors [1][2]. Group 1: Regulatory Actions and Violations - Renfu Pharmaceutical has been officially designated as "ST Renfu" due to multiple violations, including significant fund occupation and false financial reporting [1][2]. - The total fines imposed on Renfu Pharmaceutical and Contemporary Group amount to 36.7 million yuan, reflecting the severity of the violations [1][4]. - The investigation revealed that from 2020 to 2022, Renfu Pharmaceutical was involved in non-operational fund occupation totaling 12.785 billion yuan, significantly impacting its net assets [2][3]. Group 2: Financial Misconduct Details - The company engaged in improper related-party transactions, purchasing assets from a closely related entity for 1.645 billion yuan, which was not disclosed in its financial reports [3][4]. - Renfu Pharmaceutical's financial reports from 2020 to 2022 contained false records, inflating net profits by 143 million yuan, 72 million yuan, and 91 million yuan respectively [3][4]. - The concealment of related-party relationships by Contemporary Group led to further violations, complicating Renfu Pharmaceutical's compliance with disclosure regulations [4]. Group 3: Corporate Restructuring and Future Outlook - Following the financial turmoil, the controlling stake of Renfu Pharmaceutical has shifted to China Merchants Group, which has invested 11.8 billion yuan to acquire a 23.70% voting power [6][7]. - The restructuring plan has been approved by the court, leading to significant changes in the board and management of Renfu Pharmaceutical [7]. - Despite a decline in revenue by 6.58% to 17.883 billion yuan in the first three quarters of 2025, the company reported a net profit increase of 6.22% to 1.689 billion yuan, indicating potential recovery under new management [7].

Core Viewpoint - The ongoing investigation into "Contemporary System" highlights severe regulatory scrutiny over the misuse of control by major shareholders, particularly concerning the financial misconduct of companies like Renfu Pharmaceutical and its former controlling shareholder, Contemporary Group [1][2]. Group 1: Regulatory Actions and Violations - Renfu Pharmaceutical has been officially designated as ST (Special Treatment) due to multiple violations, including significant fund occupation and false financial reporting, leading to a total fine of 36.7 million yuan for both Renfu and Contemporary Group [1][2]. - The investigation revealed four main violations by Renfu Pharmaceutical from 2020 to 2022, including non-operational fund occupation totaling 12.785 billion yuan, which represented a significant percentage of the company's audited net assets during those years [3]. - The second violation involved undisclosed related-party transactions, where Renfu's subsidiaries purchased assets from a closely related company for 1.645 billion yuan, which was not reported due to a lack of timely disclosure from Contemporary Group [4]. - The third violation was the manipulation of net profits through off-balance-sheet entities, resulting in inflated profits in annual reports for 2020, 2021, and the first half of 2022 [5]. - The fourth violation involved the concealment of related-party relationships, which led to undisclosed transactions that affected Renfu's financial reporting [5]. Group 2: Market Reactions and Future Outlook - Following the regulatory penalties, Renfu Pharmaceutical's stock initially dropped but subsequently rebounded, indicating a market shift in focus towards the company's future governance and resource framework under new management [2]. - The company has stated that all past violations have been rectified and will not impact future operations, suggesting a stabilization in its business activities [6]. - The restructuring of Contemporary Group has led to the appointment of China Merchants Group as the new controlling entity of Renfu Pharmaceutical, which is expected to enhance the company's governance and operational capabilities [7][8]. - As of the first three quarters of 2025, Renfu Pharmaceutical reported revenues of 17.883 billion yuan, a year-on-year decrease of 6.58%, while net profit increased by 6.22% to 1.689 billion yuan [9].

Core Points - The company received a corrective action decision from the Gansu Securities Regulatory Bureau on December 5, 2025, regarding governance issues [1] - The investigation revealed that personnel from the indirect controlling shareholder exceeded their authority by participating in the daily management of the listed company, compromising its independence [1] - The former chairman Ye Mao and the current chairman Wu Xiaobo are held primarily responsible for the violations [1] Summary by Categories Regulatory Actions - The company was issued a corrective action decision by the Gansu Securities Regulatory Bureau, indicating regulatory scrutiny [1] - The decision is based on violations of the Corporate Governance Guidelines, specifically Article 68 [1] Governance Issues - Personnel from the indirect controlling shareholder opened accounts in the company's OA system and participated in management decisions beyond their authority [1] - This situation raises concerns about the company's independence and governance practices [1] Accountability - The former chairman Ye Mao and the current chairman Wu Xiaobo are identified as primarily responsible for the governance violations [1]